Glucocorticoid reduction with baricitinib in rheumatoid arthritis refractory to prior therapies: a 24-week real-world analysis

IntroductionIn a real-world cohort of rheumatoid arthritis (RA) patients who were unable to discontinue glucocorticoids (GCs) despite prior therapies, we aimed to evaluate the GC-sparing effect of baricitinib (BARI) and to identify clinical factors associated with GC reduction.Materials and methodsT...

Полное описание

Библиографические подробности

Главные авторы:	Takashi Yamane, Ayaka Inoue, Noriaki Yasuda, Takahisa Ohnishi, Akira Hashiramoto
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2026-03-01
Серии:	Frontiers in Medicine
Предметы:	baricitinib difficult-to-treat rheumatoid arthritis glucocorticoid tapering Janus kinase inhibitor real-world study rheumatoid arthritis
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fmed.2026.1797242/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!